Abstract
Stagnation of therapeutic options is a prominent feature of valvular aortic stenosis(AS). Invasive therapeutic options in the form of open heart aortic valve surgery or transcatheter aortic valve implantation (TAVI) are still the only therapeutic options until the moment. Decoding the mystery of AS morphogenesis is a challenging endeavor. It is only possible by multidisciplinary approach emanating from epidemiological back ground. Eagle eye observations of clinical correlates as well as prudent research in the molecular , genetic and epigenetic arena targeting decoding the genesis involved in bicuspid aortic valve formation are critical demands to throw stone in the stagnant lake. Hybrid pharmaceutical therapies combined with effective physical therapies will pave the way for future breakthroughs targeting noninvasive therapeutic options for valvular aortic stenosis or even aborting the disease in human species.